New combo aims to erase hidden myeloma after transplant
NCT ID NCT05690984
First seen Jan 05, 2026 · Last updated May 24, 2026 · Updated 20 times
Summary
This study tests whether a three-drug combination (isatuximab, lenalidomide, and dexamethasone) can eliminate tiny amounts of multiple myeloma that remain in the bone marrow after a stem cell transplant. It enrolls 30 adults whose cancer is still detectable by a sensitive test. The goal is to see if the treatment can make the cancer undetectable, but ongoing management is still needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
Conditions
Explore the condition pages connected to this study.